PTK2 and prostate carcinoma: TM4SF5 was highly expressed in liver (Lee et al., 2008) and prostate cancers (Muller-Pillasch et al., 1998) and interacted with integrins α2, α5, and β1, EGFR, IL6R, CD151, FAK, and c-Src (Lee, 2014).